Haleon PLC Sponsored ADR (NYSE:HLN) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Haleon PLC Sponsored ADR (NYSE:HLN) have received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, three have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $4.90.

Several equities research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a research note on Wednesday, September 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Friday, September 25th. Royal Bank Of Canada restated a “sector perform” rating on shares of Haleon in a report on Tuesday, August 11th. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research report on Wednesday, September 23rd. Finally, Zacks Research downgraded Haleon from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 22nd.

Institutional Investors Weigh In On Haleon

Hedge funds and other institutional investors have recently made changes to their positions in the company. Mondrian Investment Partners LTD bought a new stake in shares of Haleon during the 3rd quarter worth approximately $158,737,000. Arrowstreet Capital Limited Partnership boosted its holdings in Haleon by 82.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company’s stock valued at $146,892,000 after acquiring an additional 6,647,329 shares during the period. Bank of America Corp DE grew its position in Haleon by 17.0% in the 1st quarter. Bank of America Corp DE now owns 10,934,228 shares of the company’s stock valued at $109,452,000 after acquiring an additional 1,586,230 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich grew its position in Haleon by 4.9% in the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,701,182 shares of the company’s stock valued at $42,409,000 after acquiring an additional 219,567 shares during the last quarter. Finally, Royal Bank of Canada grew its position in Haleon by 8.5% in the 1st quarter. Royal Bank of Canada now owns 3,063,916 shares of the company’s stock valued at $30,671,000 after acquiring an additional 238,841 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Trading Down 14.5%

Shares of NYSE HLN opened at $8.55 on Friday. The business’s 50 day moving average is $9.56 and its two-hundred day moving average is $9.78. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.69 and a quick ratio of 0.52. Haleon has a 1-year low of $8.38 and a 1-year high of $11.28. The stock has a market capitalization of $37.68 billion, a P/E ratio of 21.94, a PEG ratio of 2.26 and a beta of 0.14.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.